A CD276 Antibody Guided Missile with One Warhead and Two Targets: The Tumor and Its Vasculature

Publication date: 10 April 2017
Source:Cancer Cell, Volume 31, Issue 4
Author(s): Kabir A. Khan, Robert S. Kerbel
In this issue of Cancer Cell, Seaman et al. demonstrate that antibody drug conjugates (ADCs) against CD276 expressed by tumor cells and tumor vasculature have promising anti-tumor activity while showing little toxicity. Importantly, these agents have the potential to target both angiogenic vessels and non-angiogenic vessels co-opted by tumor cells.

Teaser

In this issue of Cancer Cell, Seaman et al. demonstrate that antibody drug conjugates (ADCs) against CD276 expressed by tumor cells and tumor vasculature have promising anti-tumor activity while showing little toxicity. Importantly, these agents have the potential to target both angiogenic vessels and non-angiogenic vessels co-opted by tumor cells.


http://ift.tt/2p7iao3